AU Patent

AU2020328028B2 — Crystalline forms of CFTR modulators

Assigned to Vertex Pharmaceuticals Inc · Expires 2025-03-06 · 1y expired

What this patent protects

Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also d…

USPTO Abstract

Crystalline forms of Compound I: Formula (I) pharmaceutically acceptable salts thereof, and solvates and hydrates thereof are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed.

Drugs covered by this patent

Patent Metadata

Patent number: AU2020328028B2
Jurisdiction: AU
Classification: —
Expires: 2025-03-06
Drug substance claim: No
Drug product claim: No
Assignee: Vertex Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.